Last deal
Amount
Stage
Date
all rounds
Total amount
Financing round
General
About Company
Industry
Sector :
Subsector :
Keywords :
Contacts
Website URL
Similar Companies998
Bio-Nucleonics
Bio-Nucleonics develops radiopharmaceuticals for the treatment of oncological and cardiological diseases.
Sector
Subsector
Keywords
Location
Oncomatryx
Oncomatryx is a biopharmaceutical company focused on the tumor microenvironment.
Sector
Subsector
Location
total rounds
total raised
Antengene Corporation
Antengene is a global biopharmaceutical company focused on developing innovative oncology therapies.
Sector
Subsector
Location
total rounds
total raised
Millennium Pharmaceuticals
Millennium Pharmaceuticals is a biopharmaceutical company that develops and commercializes cancer medicines.
Sector
Subsector
Keywords
Location
total rounds
M&A Details1
Financials
Funding Rounds2
Number of Funding Rounds
Money Raised
Their latest funding was raised on 25.08.2023. Their latest investor Access Biotechnology. Their latest round Series B
Deep Track Capital
Deep Track Capital is a Greenwich-based investment firm focused on life sciences.
Sector
Subsector
Location
count Of Investments
count Of Exists
Forbion
Netherlands-based venture capital firm investing in life sciences and MedTech companies.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Co-Investors
Investors8
Number of lead investors
Number of investors
Access Biotechnology
Access Biotechnology invests in private and public biopharma companies.
Sector
Subsector
Location
count Of Investments
count Of Exists
Dan Becker
Dan Becker joined New Leaf Venture Partners in 2015. Prior to joining New Leaf, Dan was a Principal at the Boston Consulting Group where he was a core member of their Health Care practice and led projects across the health care sector with an emphasis on biopharma R&D. Prior to BCG, Dan was a Research Fellow at Harvard Medical School, and trained clinically in internal medicine and nephrology at Brigham and Women’s Hospital and Massachusetts General Hospital. Dan graduated summa cum laude with a B.S. in Physiology from the University of Illinois at Urbana-Champaign, and obtained both his M.D. and Ph.D. (Cellular and Molecular Biology) degrees from the University of Michigan. Dan has co-authored multiple scientific publications in peer-reviewed journals, including Nature Genetics and the Journal of Cell Biology. He is Board-certified in Internal Medicine.
current job
count Of Investments
Atlas Ventures
Atlas Ventures is an early-stage VC fund focused on investing in tech and tech-enabled businesses in Southeast Asia.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Kevin Bitterman
Kevin is the interim president of Editas Medicine and a principal at Polaris Partners. He joined Polaris in 2004 and focuses on investments in health care. Kevin is a co-founder of Genocea Biosciences and Sirtris Pharmaceuticals (acquired by GSK) and was the founding CEO at Visterra Inc. (formerly Parasol Therapeutics). He currently represents Polaris as a director of InSeal Medical, Genocea Biosciences, Kala Pharmaceuticals, Neuronetics, Inc., Visterra Inc., Taris Biomedical and Vets First Choice. Additionally, he is a board observer to Arsenal Medical and 480 Biomedical.Kevin holds a Ph.D. in genetics from Harvard Medical School. His doctoral research focused on the molecular regulation of caloric restriction and on modulation of a novel class of protein deacetylases.
current job
Nextech Invest
Nextech Invest is a venture capital and private equity firm that focuses on precision therapies in oncology.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Activity
Recent News5
The graph reveals the ratio (%) of positive news articles in a chosen time range